Therapeutic Area
Metabolic Disease CDMOs
Compare CDMOs with metabolic disease manufacturing expertise for GLP-1 agonists, insulin analogs, and oral antidiabetics. Filter by peptide capabilities, dosage form, and scale.
101 companies listed
About Metabolic Disease Drug Manufacturing
The metabolic disease space is experiencing unprecedented demand growth, driven by GLP-1 receptor agonists (semaglutide, tirzepatide) for diabetes and obesity. Global GLP-1 manufacturing capacity is severely constrained, with demand outstripping supply by an estimated 2-3x. CDMOs with peptide synthesis, fermentation-based peptide production, and prefilled pen/syringe fill-finish capabilities are the most sought-after partners in pharma.
Peptide manufacturing is the bottleneck. GLP-1 agonists are peptides produced either by solid-phase peptide synthesis (SPPS) or recombinant DNA technology. SPPS is suitable for shorter peptides but faces scale limitations. Recombinant production in E. coli or yeast (Pichia pastoris) enables larger scale but requires fermentation expertise, refolding optimization, and complex purification. CDMOs that can offer both approaches provide sponsors with optionality.
Device integration drives complexity. Most metabolic disease injectables are delivered via pen injectors or autoinjectors for patient self-administration. CDMOs need cartridge filling capability (3mL cartridges for pens), device assembly experience, and combination product regulatory knowledge. The fill-finish step for cartridges requires different equipment and expertise than standard vial filling.
Companies (101)
UPM Pharmaceuticals
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of semi-solid and oral solid dose products. Operating from a 475,000 sq ft cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 30+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
Small Molecule Drug ProductOral Solid DoseFormulation Development
Vetter Pharma
Germany
Vetter Pharma is a leading global Contract Development and Manufacturing Organization specializing in aseptic fill-and-finish services for injectable drug products. Headquartered in Ravensburg, Germany, Vetter operates as an independent, family-owned business with over 75 years of experience.
Frequently Asked Questions
Why is GLP-1 manufacturing capacity so constrained?+
Three factors converge. First, the clinical success of semaglutide and tirzepatide expanded the addressable market from 500 million diabetes patients to over 1 billion when obesity is included. Second, peptide manufacturing (whether synthetic or recombinant) is inherently lower throughput than small molecule or antibody manufacturing. Third, building new peptide manufacturing capacity takes 3-5 years from ground-breaking to GMP production. The gap between demand and supply will persist through at least 2027-2028.
What capabilities should a metabolic disease CDMO have?+
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
